We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.47B
AUM Growth
+$39M
Cap. Flow
-$32.3M
Cap. Flow %
-2.19%
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$21.4M
2
PFE icon
Pfizer
PFE
+$19.4M
3
VEEV icon
Veeva Systems
VEEV
+$17.8M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$11.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$11.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13M
3
LIVN icon
LivaNova
LIVN
+$11.9M
4
NVCR icon
NovoCure
NVCR
+$11.7M
5
CNC icon
Centene
CNC
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.98%
2 Industrials 1.94%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
76
Tenet Healthcare
THC
$20.9B
$5.69M 0.39%
+85,000
New +$5.27M
MYOV
77
DELISTED
Myovant Sciences Ltd.
MYOV
$5.69M 0.39%
250,000
+25,000
+11% +$526K
ANNX icon
78
Annexon
ANNX
$883M
$5.63M 0.38%
250,000
+70,000
+39% +$1.55M
OSH
79
DELISTED
Oak Street Health, Inc.
OSH
$5.56M 0.38%
95,000
-20,000
-17% -$1.19M
KYNB
80
Kyntra Bio
KYNB
$28.2M
$5.33M 0.36%
8,000
– –
VRAY
81
DELISTED
ViewRay, Inc.
VRAY
$5.12M 0.35%
775,000
– –
PGNY icon
82
Progyny
PGNY
$2.18B
$4.72M 0.32%
+80,000
New +$4.49M
SAGE
83
DELISTED
Sage Therapeutics
SAGE
$4.26M 0.29%
+75,000
New +$5.3M
ARNA
84
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.09M 0.28%
60,000
– –
IMCR icon
85
Immunocore
IMCR
$1.73B
$3.52M 0.24%
+90,000
New +$3.47M
INNV icon
86
InnovAge Holding
INNV
$1.48B
$3.2M 0.22%
+150,000
New +$3.43M
SPRY icon
87
ARS Pharmaceuticals
SPRY
$587M
$3.09M 0.21%
+100,000
New +$3.21M
IONS icon
88
Ionis Pharmaceuticals
IONS
$9.46B
$2.99M 0.2%
75,000
– –
GKOS icon
89
Glaukos
GKOS
$10.7B
$2.97M 0.2%
35,000
– –
HRMY icon
90
Harmony Biosciences
HRMY
$2.27B
$2.82M 0.19%
+100,000
New +$3M
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$2.2M 0.15%
265,000
– –
DCPH
92
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.2M 0.15%
60,000
– –
PVLA
93
Palvella Therapeutics
PVLA
$2.19B
$1.15M 0.08%
3,750
– –
LIVN icon
94
LivaNova
LIVN
$4.21B
$841K 0.06%
10,000
-145,000
-94% -$11.9M
ADVM
95
DELISTED
Adverum Biotechnologies
ADVM
– –
-65,000
Closed -$6.41M
AMWL icon
96
American Well
AMWL
$231M
– –
-9,708
Closed -$3.37M
GDRX icon
97
GoodRx Holdings
GDRX
$1.25B
– –
-75,000
Closed -$2.93M
RPRX icon
98
Royalty Pharma
RPRX
$25.8B
– –
-130,000
Closed -$5.67M
NXGN
99
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-150,000
Closed -$2.71M
NUAN
100
DELISTED
Nuance Communications, Inc.
NUAN
– –
-90,000
Closed -$3.93M
1 2 3
4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rhenman & Partners Asset Management held 101 positions worth $1.47B, up 2.7% from $1.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q2 2021 filing shows 9 new, 29 increased, 33 reduced and 7 closed positions. Its largest new stake was Pfizer: 500,000 shares worth $19.6M. The largest sale was Johnson & Johnson, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q2 2021 buy was Pfizer: 500,000 shares worth $19.6M.
  • Rhenman & Partners Asset Management added most to Biogen in Q2 2021, an estimated $21.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $41.4M.
  • Rhenman & Partners Asset Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $6.41M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $1.47B portfolio in Q2 2021.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 7 in Q2 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 2.7% quarter-over-quarter to $1.47B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.